Exhibit 99.1
Johnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the KenvueSeparation
•
Company expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of 7.5% - 8.5%, andAdjusted Operational Sales Growth of 6.2% - 7.2%; Figures exclude the COVID-19 Vaccine
•
Company expects 2023 Adjusted Reported Earnings Per Share (EPS) of $10.00 - $10.10, reflecting increased growth of12.5% at the mid-point and Adjusted Operational EPS of $9.90 - $10.00, reflecting increased growth of 11.5% at the mid-point
•
Company reduced outstanding share count by approximately 191 million; 2023 guidance reflects only a partial-year benefitof approximately 73.5 million shares or $0.28 benefit to EPS
•
Company secured $13.2 billion in cash proceeds from the Kenvue debt offering and initial public offering and maintains 9.5%of equity stake in Kenvue
•
Company maintains its quarterly dividend of $1.19 per share
New Brunswick, N.J. (August 30, 2023)
– Johnson & Johnson (NYSE: JNJ) (“the Company”) today announced updates to its financials and2023 guidance which reflect its operations as a company focused on transformational innovation in Pharmaceutical and MedTech. TheCompany has published a recorded webinar for investors to provide additional context behind the updated financials and 2023 guidancefound in this release, which may be accessed by visiting the Investors section of the Company's website at
webcasts & presentations
.
“The completion of this transaction uniquely positions Johnson & Johnson as a Pharmaceutical and MedTech company focused on deliveringtransformative healthcare solutions to patients,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “We are incrediblyproud of the focus and dedication of our employees worldwide to achieve this milestone, which we are confident will unlock near- and long-term value for all of our stakeholders.”
As previously
announced
, the Company recently completed an exchange offer to finalize the separation of Kenvue Inc., formerly Johnson &Johnson’s Consumer Health business. As a result of the completion of the exchange offer, Johnson & Johnson will now present itsConsumer Health business financial results as discontinued operations, including a gain of approximately $20 billion in the third quarter of2023